Find Funding Opportunities

Find Funding Opportunities

Subscribe to Find Funding OpportunitiesRSS
Filter By:
Returning 183 results

Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed)

Notice of Special Interest
Monday, October 19, 2020
Thursday, May 16, 2024
333
NOT-NS-20-107

Funding Opportunity Purpose

This Notice encourages eligible awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222, Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). The NIH has a strong interest in the diversity of the NIH-funded workforce (see NOT-OD-20-031) and encourages institutions to diversify their populations by enhancing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences.

Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

PA
Tuesday, October 13, 2020
Monday, July 24, 2023
333
PA-20-272

Funding Opportunity Purpose

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for administrative supplements are considered prior approval requests (as described in Section 8.1.2.11 of the NIH Grants Policy Statement) and will be routed directly to the Grants Management Officer of the parent award. Although requests for administrative supplements may be submitted through this FOA, there is no guarantee that funds are available from the awarding IC or for any specific grant. All applicants are encouraged to discuss potential requests with the awarding IC. Additionally, prior to submission, applicants must review the awarding IC's web site to ensure they meet the IC's requirements. A list of those web sites is available at https://grants.nih.gov/grants/guide/admin_supp/index.htm.

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R01 Clinical Trial Not Allowed)

RFA
Thursday, September 24, 2020
Saturday, January 9, 2021
R01
RFA-MH-20-701

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required.

Role of Myeloid Cells in Persistence and Eradication of HIV-1 Reservoirs from the Brain (R21 Clinical Trial Not Allowed)

RFA
Thursday, September 24, 2020
Saturday, January 9, 2021
R21
RFA-MH-20-702

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) invites research grant applications studying mechanisms of HIV-1 persistence in myeloid cells and strategies to target this reservoir in the central nervous system. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. RFA-MH-20-701uses the R01 grant mechanism whileRFA-MH-20-702uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism, while applicants with preliminary data may wish to apply using the R01 mechanism.

BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed)

RFA
Thursday, September 17, 2020
Wednesday, October 20, 2021
U01
RFA-MH-20-556

Funding Opportunity Purpose

This FOA is related to the transformative project, "A Cell Type-Specific Armamentarium for Understanding Brain Function and Dysfunction," described in the "The BRAIN Initiative 2.0: From Cells to Circuits, Toward Cures" report of the Advisory Committee to the NIH Director BRAIN Initiative Working Group 2.0.

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

RFA
Wednesday, September 16, 2020
Thursday, September 8, 2022
UG3/UH3
RFA-NS-21-010

Funding Opportunity Purpose

Reissue of RFA-NS-20-010: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and development of promising small molecule and biologic hits/leads towards clinical trials. Applicants must have a promising hit/lead, robust biological rationale for the intended approach, and identified assays for optimization of the agent. The scope of this program includes optimization and early development activities, IND-enabling studies, and assembly of Investigational New Drug (IND) application. This is a milestone-driven phased cooperative agreement program involving participation of NIH program staff in the development of the project plan and monitoring of research progress.

Notice of Special Interest: Administrative Supplement for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supp)

Notice of Special Interest
Friday, September 11, 2020
Sunday, October 30, 2022
NOT-NS-20-038

Funding Opportunity Purpose

This Notice of Special Interest encourages administrative supplements for the NINDS Research Education Program for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25, PAR-13-384 and subsequent reissuances)

Notice of Special Interest (NOSI): Research in the Emergency Setting

Notice of Special Interest
Tuesday, September 8, 2020
Thursday, September 8, 2022
NOT-NS-20-005

Funding Opportunity Purpose

Purpose The purpose of this Notice is to announce an interest in research addressing patients with emergency medical conditions, including trauma. Background Over 145 million people are seen in emergency departments across the US. Emergency departments are the source of twelve million admissions, or 35% of all hospital admissions and 14% of all outpatient visits. This includes over 27 million children under the age of 15, 23 million adults over the age of 65 and over 42 million visits for injuries and major trauma. When they learn of a patient's new symptoms, primary care providers often use the emergency department to obtain rapid diagnostic tests and a treatment plan. Emergency Departments are the only component of the country's healthcare system that is accessible at any time of the day or night, and by law they provide treatment regardless of the ability to pay. Rapid assessment and treatment within the first minutes or hours after the onset of illness plays a major role in determining both the trajectory of recovery and future healthcare costs. Research in the emergency setting offers a unique opportunity to improve not only the treatment of acute life-threatening disorders, but also a spectrum of common disorders that encompass a considerable burden of illness and account for a major component of health care costs.

NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed)

RFA
Wednesday, September 2, 2020
Saturday, December 19, 2020
R01
RFA-AT-21-003

Funding Opportunity Purpose

The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders (for further information, see https://neuroscienceblueprint.nih.gov/). The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting neural circuits connecting peripheral organs/tissues with the central nervous system via peripheral ganglia. For this FOA, interoception science includes studies of the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself. The FOA encourages projects that combine diverse expertise and use innovative approaches to delineate interoceptive mechanisms at the molecular, cellular, circuitry, functional, and/or behavioral levels. Outcomes of this research will lay a critical foundation for future translational and clinical research on interoception as well as its roles in nervous system disorders. Studies of interoceptive neural circuits exclusively within the central nervous system may consider seeking for BRAIN INITIATIVE funding opportunities.

Notice of Special Interest: Administrative Supplements for Connecting Pre-mortem Clinical Information with Post-Mortem Brain Analysis

Notice of Special Interest
Wednesday, August 26, 2020
Tuesday, June 29, 2021
333
NOT-NS-21-001

Funding Opportunity Purpose

The Lewy Body Dementias (LBD) are frequently misdiagnosed or underdiagnosed during life, and despite the development of diagnostic criteria at multiple expert consensus conferences, the gold standard for diagnosis remains post-mortem brain analysis. Improvement in diagnostic accuracy during life, and the development of good quality diagnostic biomarkers, would be greatly facilitated if comprehensive, longitudinal clinical and biological data obtained on patients during life were regularly linked with detailed post-mortem brain examination. In response to recommendations from the Alzheimer's Disease Related Dementias (ADRD) Summits convened by the NINDS in 2013, 2016, and 2019, longitudinal clinical data and biospecimens are being collected from patients with LBD and shared with the research community through the Parkinsons Disease Biomarker Program (PDBP). The PDBP is an NINDS-funded resource that collects standardized clinical data and biospecimens longitudinally on patients with Parkinson's Disease (PD) and PD-related disorders (including LBD) with the goal of accelerating the pace of biomarkers research. The PDBP currently has data and biospecimens on about 1900 subjects, some of whom have gone to autopsy, though relatively little post-mortem data on these subjects is available in PDBP at this time. This NOSI encourages researchers with extensive pre- and post-mortem data on patients with LBD to apply for supplemental funds to be used for the purpose of adding this data to the existing NINDSPDBP repository. Supplements may be requested by: Researchers who have previously contributed clinical and biospecimen data to the PDBP on patients with LBD while alive, and who wish to add the post-mortem autopsy data they have collected on the same patient(s) after their death.

Pages